Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 510-518

  Lin, Jen Der ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Autopsy; Fine needle aspiration cytology; Thyroglobulin; Thyroidectomy

Indexed keywords

CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2; DYSADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN 3; IODINE 131; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; PROTEIN S 100 A4; SURVIVIN; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AUTOPSY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; DISTANT METASTASIS; FEMALE; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; OCCULT CANCER; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SUBTOTAL THYROIDECTOMY; THYROID PAPILLARY CARCINOMA; THYROID PAPILLARY MICROCARCINOMA; TREATMENT INDICATION; TREND STUDY; TUMOR VOLUME;

EID: 77956917820     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9242-8     Document Type: Review

References (74)

1. Heckman CA, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008;68: 4754-62. doi:10.1158/0008-5472.CAN-07- 5809.
2. Tammela T, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454: 656-60. doi:10.1038/nature07083.
3. Gerard AC, et al. Relationships between cell division, expression of growth factors and microcirculation in the thyroids of Tg-A2aR transgenic mice and patients with Graves' disease. J Endocrinol. 2003;177:269-77. doi:10.1677/joe.0.1770269. (Pubitemid 36656400)
4. Poulaki V, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab. 2003;88:5392-8. doi:10.1210/jc.2003-030389. (Pubitemid 37452744)
5. Lin JD. Papillary thyroid carcinoma with lymph node metastases. Growth Factors. 2007;25:41-9. doi:10.1080/08977190601000095. (Pubitemid 46672285)
6. Howlett DC, Speirs A. The thyroid incidentaloma-ignore or investigate? J Ultrasound Med. 2007;26:1367-71.
7. Phitayakorn R, McHenry CR. Incidental thyroid carcinoma in patients with Graves' disease. Am J Surg. 2008;195:292-7. doi: 10.1016/j.amjsurg.2007.12.006. (Pubitemid 351625108)
8. Mazeh H, Divino C, Nagi C, Bleiweiss IJ, Weber K. Incidental etastatic microcarcinoma of the thyroid identified after total parathyroidectomy. Thyroid. 2007;17:685-7. doi:10.1089/thy.2006.0295. (Pubitemid 47311560)
9. de Matos PS, Ferreira AP, Ward LS. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series. Endocr Pathol. 2006;17:165-73. doi:10.1385/EP:17:2:165. (Pubitemid 44965905)
10. Sobin LH, UICC. In: Wittekind Ch, editor. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002. p. 52-6.
11. Rosário PW, et al. Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid. 2007;17:1225-8. doi:10.1089/thy.2006.0254.
12. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245:366-78. doi:10.1097/01.sla.0000250445.92336.2a. (Pubitemid 46673133)
13. Döbert N, Menzel C, Oeschger S, Grünwald F. Differentiated thyroid carcinoma: the new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients. Thyroid. 2004;14:65-70. doi:10.1089/105072504322783867. (Pubitemid 38282939)
14. Rossi R, et al. Differentiated thyroid cancers 11-20 mm in diameter have clinical and histopathologic characteristics suggesting higher aggressiveness than those
15. Lin JD, et al. Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging. Surg Oncol. 2007;16: 107-13. doi:10.1016/j.suronc.2007.05.004. (Pubitemid 47334953)
16. Delellis RA, Lloyd RV, Heitx PU, et al. Pathology and genetics of tumors of endocrine organs. In: World Health Organization of tumours. IARC, Lyon; 2004. pp. 73-6.
17. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-24.
18. Deveci MS, Deveci G, LiVolsi VA, Gupta PK, Baloch ZW. Concordance between thyroid nodule sizes measured by ultrasound and gross pathology examination: effect on patient management. Diagn Cytopathol. 2007;35:579-83. doi:10.1002/dc.20714. (Pubitemid 47439743)
19. Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol. 2006;13:69-75. doi:10.1097/01.pap.0000213006.10362.17. (Pubitemid 44350513)
20. Lissak B, Vannetzel JM, Gallouedec N, Berrod JL, Rieu M. Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. J Endocrinol Invest. 1995;18:813-6.
21. Russo F, et al. Clinico-pathological study of microcarcinoma of the thyroid. Minerva Chir. 1997;52:891-900.
22. Kwak JY, et al. Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid. 2008;18:609-14. doi:10.1089/thy.2007. 0345. (Pubitemid 351918452)
23. Lin JD, Kuo SF, Chao TC, Hsueh C. Incidental and nonincidental papillary thyroid microcarcinoma. Ann Surg Oncol. 2008;15: 2287-92. doi:10.1245/s10434- 008-9958-2.
24. Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary icrocarcinoma. World J Surg. 2008;32:747-53. doi:10.1007/s00268-007-9453-0.
25. Pelizzo MR, et al. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol. 2006;32:1144-8. doi:10.1016/j.ejso.2006.07.001. (Pubitemid 44774404)
26. Roti E, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab. 2006;91:2043-6. doi:10.1210/jc.2005-2372. (Pubitemid 43855001)
27. Hay ID, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139-46.
28. Rodriguez JM, et al. Papillary thyroid microcarcinoma: clinical study and prognosis. Eur J Surg. 1997;163:255-9.
29. Chow SM, et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31-40. doi:10.1002/cncr.11442. (Pubitemid 36741122)
30. Baudin E, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998;83:553-9. doi: 10.1002/(SICI)1097- 0142(19980801)83:3\553::AID-CNCR25[3.0.CO;2-U. (Pubitemid 28354512)
31. Mansberg R, Son H, Kean AM. Occult carcinoma of the thyroid presenting with orbital metastasis. Clin Nucl Med. 2006;31:109-11. doi:10.1097/01.rlu. 0000196605.16989.ef. (Pubitemid 44366753)
32. Kini S, et al. Occult medullary carcinoma of thyroid with lymph node metastases: a case report. Acta Cytol. 2008;52:105-8.
33. Hubert JP Jr, Kiernan PD, Beahrs OH, McConahey WM, Woolner LB. Occult papillary carcinoma of the thyroid. Arch Surg. 1980;115:394-8.
34. Silliphant WM, Klinck GH, Levitin MS. Thyroid cancer and death. A clinicopathological study of 193 autopsies. Cancer. 1964;17:513-25. doi:10.1002/1097-0142(196404)17:4<513::AIDCNCR2820170413>3.0.CO;2-2.
35. Silverberg SG, Vidone RA. Carcinoma of the thyroid in surgical and postmortem material. Analysis of 300 cases at autopsy and literature review. Ann Surg. 1966;164:291-9.
36. Sampson RJ, Key CR, Buncher CR, Iijima S. Thyroid carcinoma in Hiroshima and Nagasaki. I. Prevalence of thyroid carcinoma at autopsy. JAMA. 1969;209:65-70. doi:10.1001/jama.209.1.65.
37. Sampson RJ, Woolner LB, Bahn RC, Kurland LT. Occult thyroid carcinoma in Olmsted County, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer. 1974;34:2072-6. doi:10.1002/1097-0142(197412)34: 6<2072::AIDCNCR2820340629>3.0.CO;2-#.
38. Franssila KO, Harach HR. Occult papillary carcinoma of the thyroid in children and young adults. A systemic autopsy study in Finland. Cancer. 1986;58:715-9. doi:10.1002/1097-0142(19860801)58:3<715::AID- CNCR2820580319>3.0.CO;2-P.
39. Ottino A, Pianzola HM, Castelletto RH. Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer. 1989; 64:547-51. doi:10.1002/1097-0142(19890715)64:2<547::AIDCNCR2820640232>3.0.CO;2-N.
40. Bisi H, et al. The prevalence of unsuspected thyroid pathology in 300 sequential autopsies, with special reference to the incidental carcinoma. Cancer. 1989;64:1888-93. doi:10.1002/1097-0142(19891101)64:9\1888::AID- CNCR2820640922[3.0.CO;2-C.
41. Autelitano F, Spagnoli LG, Santeusanio G, Villaschi S, Autelitano M. Occult carcinoma of the thyroid gland: an epidemiological study of autopsy material. Ann Ital Chir. 1990;61:141-6.
42. Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer. 1990;65:1173-9. doi:10.1002/1097-0142(19900301)65:5<1173::AID-CNCR2820650524>3.0.CO;2-2.
43. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71:4022-9.doi:10.1002/1097-0142(19930615)71:12<4022:: AID-CNCR2820711236>3.0.CO;2-O.
44. Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathology. 1993;23:319-25. doi:10.1111/j.1365-2559.1993.tb01214.x.
45. Avetisian IL, Petrova GV. Latent thyroid pathology in residents of Kiev, Ukraine. J Environ Pathol Toxicol Oncol. 1996;15:239-43.
46. Mitselou A, Vougiouklakis T, Peschos D, Dallas P, Agnantis NJ. Occult thyroid carcinoma. A study of 160 autopsy cases. The first report for the region of Epirus-Greece. Anticancer Res. 2002;22:427-32.
47. Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am J Otolarygol. 2005;26:87-90. doi:10.1016/j.amjoto.2004.08.003. (Pubitemid 40312068)
48. Jank S, et al. The diagnostic value of ultrasonography to detect occult lymph node involvement at different levels in patients with squamous cell carcinoma in the maxillofacial region. Int J Oral Maxillofac Surg. 2003;32:39-42. doi:10.1054/ijom.2002.0326. (Pubitemid 36284851)
49. King DL, Stack BC Jr, Spring PM, Walker R, Bodenner DL. Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg. 2007;137:400-4. doi:10.1016/j.otohns.2007.02.037. (Pubitemid 47320854)
50. Lin KD, et al. Clinical presentations and predictive variables of thyroid microcarcinoma with distant metastasis. Int Surg. 1997;82:378-81.
51. Besic N, Pilko G, Petric R, Hocevar M, Zgajnar J. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol. 2008;97:221-5. doi:10.1002/jso.20935. (Pubitemid 351312160)
52. Batistatou A, et al. Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. Endocr Pathol. 2008;19:197-202. doi:10.1007/s12022-008-9035-1.
53. Cvejic D, et al. Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. Pathology. 2008;40:475-80.doi:10.1080/00313020802026989. (Pubitemid 351950881)
54. Antonaci A, et al. Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol Rep. 2008;20:63-7.
55. Min HS, et al. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol. 2008;21:748-55. doi:10.1038/modpathol.2008.51. (Pubitemid 351744841)
56. Lim DJ, et al. Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid. 2007;17:883-8. doi:10.1089/thy.2007.0001. (Pubitemid 47610425)
57. Londero SC, et al. Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? Acta Oncol. 2008;47:451-7. doi:10.1080/ 02841860701630242. (Pubitemid 351414932)
58. Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinom's but is not associated with gene amplification. J Clin Endocrinol Metab. 2002;87:1810-3. doi:10.1210/jc.87.4. 1810.
59. Pestell RG, et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 1999;20:501-34. doi:10.1210/er.20.4.501.
60. Lim YC, Choi EC, Yoon YH, Kim EH, Koo BS. Central lymph node metastases in unilateral papillary thyroid microcarcinoma. Br J Surg. 2009;96:253-7. doi:10.1002/bjs.6484.
61. Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J. 1999;46:209-16. doi: 10.1507/endocrj.46.209.
62. Pisanu A, Reccia I, Nardello O, Uccheddu A. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg. 2009;33:460-8. doi:10.1007/s00268-008-9870-8.
63. Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol. 2008;215:145-54. doi:10.1002/path.2342. (Pubitemid 351786033)
64. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998;83:4116-22. doi:10.1210/jc.83.11.4116.
65. Lin X, Finklestein S, Zhu B, Silverman J. Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol. 2008;41:195-203. doi:10.1677/JME-08-0063.
66. Biscolla RP, et al. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid. 2004; 14:946-52. doi:10.1089/thy.2004.14.946.
67. Cupisti K, et al. Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter. Endocr J. 2005;52:281-5. doi:10.1507/endocrj.52.281. (Pubitemid 40745721)
68. Behrand M, von Wasielewski R, Brabant G. Simultaneous medullary and papillary microcarcinoma of thyroid in a patient with secondary hyperparathyroidism. Endocr Pathol. 2002;13:65-73. doi:10.1385/EP:13:1:65. (Pubitemid 34665117)
69. Satge D, Grob JC, Pusel J, Methlin G. Thyroid microcarcinoma with a fatal outcome and 34 other unusually aggressive cases reported in the literature. Arch Anat Cytol Pathol. 1990;38:143-51.
70. Yamashita H, et al. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer. 1999;86:842-9. doi:10.1002/(SICI)1097-0142(19990901)86: 5\842::AID-CNCR21[3.0.CO;2-X. (Pubitemid 29399925)
71. Ito Y, et al. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg. 2004;28:1115-21. doi:10.1007/s00268-004-7644-5. (Pubitemid 40109861)
72. Lupoli G, et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet. 1999;353:637-9. doi:10.1016/S0140-6736(98)08004-0. (Pubitemid 29087985)
73. Avetisian IL, Gulchiy NV, Demidiuk AP, Stashuk AV. Thyroid pathology in residents of the Kiev region, Ukraine, during preand post-Chernobyl periods. J Environ Pathol Toxicol Oncol. 1996;15:233-7.
74. Furlan JC, Rosen IB. Prognostic relevance of previous exposure to ionizing radiation in well-differentiated thyroid cancer. Langenbecks Arch Surg. 2004;389:198-203. doi:10.1007/s00423-003-0424-0.